---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-124162"
form_type: "8-K"
ticker: "ELAB"
cik: "0001840563"
company_name: "PMGC Holdings Inc."
filed_at: "2025-12-22T23:59:59+00:00"
generated_at: "2026-05-16T12:27:23.233091+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PMGC subsidiaries advance drug discovery program and achieve AS9100 certification

## Summary
- NorthStrive Biosciences advances to Phase III of AI drug discovery program with YuvaBio, targeting muscle preservation via mitochondrial function.
- Phase III will generate biological data on AI-selected compounds, including cytotoxicity screening and ANT1 expression testing over 6-9 weeks.
- AGA Precision Systems achieves AS9100 certification, the globally recognized quality standard for aerospace, defense, and space industries.
- AGA is evaluating humanoid robotics integration for advanced manufacturing; no assurance of implementation or benefits.

## SEC filing metadata
- accession: 0001213900-25-124162
- form_type: 8-K
- ticker: ELAB
- cik: 0001840563
- company_name: PMGC Holdings Inc.
- filed_at: 2025-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840563/000121390025124162/0001213900-25-124162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840563/000121390025124162/ea0270503-8k_pmgchold.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-124162
- JSON: https://secwatch.observer/filing/0001213900-25-124162.json
- Plain text: https://secwatch.observer/filing/0001213900-25-124162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.